AU2023238937A1 - Anti-par2 antibodies - Google Patents

Anti-par2 antibodies Download PDF

Info

Publication number
AU2023238937A1
AU2023238937A1 AU2023238937A AU2023238937A AU2023238937A1 AU 2023238937 A1 AU2023238937 A1 AU 2023238937A1 AU 2023238937 A AU2023238937 A AU 2023238937A AU 2023238937 A AU2023238937 A AU 2023238937A AU 2023238937 A1 AU2023238937 A1 AU 2023238937A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
antibody
par2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023238937A
Other languages
English (en)
Inventor
Catherine HUTCHINGS
Alexandra Kraus
Krzysztof Okrasa
Greg Osborne
Dorothée RÜHLE
Oliver SCHLENKER
Annika SCHMID
Andrei ZHUKOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of AU2023238937A1 publication Critical patent/AU2023238937A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023238937A 2022-03-24 2023-03-24 Anti-par2 antibodies Pending AU2023238937A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2204159.4A GB202204159D0 (en) 2022-03-24 2022-03-24 Antibodies
GB2204159.4 2022-03-24
PCT/GB2023/050760 WO2023180767A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Publications (1)

Publication Number Publication Date
AU2023238937A1 true AU2023238937A1 (en) 2024-10-31

Family

ID=81449405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023238937A Pending AU2023238937A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Country Status (10)

Country Link
US (1) US20250313621A1 (https=)
EP (1) EP4499694A1 (https=)
JP (1) JP2025510815A (https=)
KR (1) KR20240161970A (https=)
CN (1) CN119137152A (https=)
AU (1) AU2023238937A1 (https=)
CA (1) CA3246035A1 (https=)
GB (1) GB202204159D0 (https=)
IL (1) IL315704A (https=)
WO (1) WO2023180767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024255639A1 (en) * 2023-04-14 2025-10-02 Triveni Bio, Inc. Dual inhibitor trypsin antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MX2019010802A (es) 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso

Also Published As

Publication number Publication date
WO2023180767A1 (en) 2023-09-28
CA3246035A1 (en) 2023-09-28
CN119137152A (zh) 2024-12-13
JP2025510815A (ja) 2025-04-15
US20250313621A1 (en) 2025-10-09
GB202204159D0 (en) 2022-05-11
KR20240161970A (ko) 2024-11-13
EP4499694A1 (en) 2025-02-05
IL315704A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
TWI528974B (zh) 用於增加肌肉生長之組合物及方法
JP7064666B2 (ja) ＦｃγＲＩＩＡに特異的な結合分子及びその使用
US20250179172A1 (en) Cd5 antibody and use thereof
KR20220025938A (ko) 항-pd-1 항체 및 이의 용도
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
TW202126693A (zh) 標靶bcma的抗體、雙專一性抗體及其用途
KR102562418B1 (ko) 항-테나신 c 항체 및 이의 용도
TW201132759A (en) Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof
AU2016293119A1 (en) Antibody molecules which bind CD79
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
US20250313621A1 (en) Anti-par2 antibodies
TW202304975A (zh) 新穎抗sema3a抗體及其用途
JP2023536629A (ja) Ｃｄ４７結合性作用剤およびその使用
JP2022540859A (ja) 新規ｂｓｓｌ抗体
JP2025503707A (ja) ガレクチン－１０抗体
WO2021043203A1 (en) Anti-cxcr2 antibodies and uses thereof
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
JP2023536630A (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
KR20250159082A (ko) Nkg2a 결합제 및 이의 용도
HK40099698A (zh) 抗sema3a抗体及其用途
HK40088986A (zh) 多聚化cd45的结合分子
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HUTCHINGS, CATHERINE; OSBORNE, GREG; SCHLENKER, OLIVER; OKRASA, KRZYSZTOF; ZHUKOV, ANDREI; SCHMID, ANNIKA; KRAUS, ALEXANDRA AND RUEHLE, DOROTHEE